BioLife Solutions, Inc. (BLFS)

From the record

BioLife Solutions, Inc.'s filings since 2017 show 9 warning events of 4 kinds: a notice about its exchange listing (8-K item 3.01, 2 times, the latest 2026-10-06); a warning not to rely on past financial statements (8-K item 4.02, the latest 2020-04-30); an auditor change (8-K item 4.01, 2 times, the latest 2022-04-07); a late-report notice (Form NT 10-K or NT 10-Q, 4 times, the latest 2023-05-11) (its current reports).

From the record

BioLife Solutions, Inc.'s 9 filed years say what it did: revenue went from $11 million in fiscal 2017 to $96 million in fiscal 2025, up 31.1% a year; it rose in 6 of 8 years; the deepest fall was 43% from fiscal 2021 to fiscal 2023; net income was positive in 1 of 9 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, BioLife Solutions, Inc.'s diluted share count grew about 4.1% a year, and dividends and buybacks returned about 0% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 45 sales (33 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-08 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, BioLife Solutions, Inc. lost about 1 cents for every dollar of shareholders' money, and gross profitability: its products earned about 15 cents per dollar of everything the company owns. Leverage: it owed about 8 cents per dollar of assets, and net share issuance: its share count grew 5.6% over the year (the filed statements).

From the record

BioLife Solutions, Inc.'s standing among 24 graded names in its industry family: revenue of $96 million in fiscal 2025 ranks in the top 35% by size; a net margin of -4.8% ranks in the top 27%; revenue growth of 8.1% a year over the last 3 filed years ranks in the bottom 38% (its annual reports).

From the record

BioLife Solutions, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is De, Greef Roderick (Chief Executive Officer, as filed), filing under that title since 2023-11-01, 3 years (top 42% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 5.6 years (top 32%); 4 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (top 24%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

BioLife Solutions, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $33 million against debt of $5 million leaves 6.9% of its assets as net cash, bottom 29% of its family; cash from operations less capital spending is 11.1% of revenue (top 24%); a gross margin of 64.6% (top 41%); research spending of 7.9% of revenue (bottom 30%) (its annual report).

From the record

BioLife Solutions, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 8.1% a year over the last three filed years against 31.1% over all 9, slowing (bottom 20% of its family); the newest year grew 28.9% (top 28%); research spending grew -4.4% a year (bottom 26%); capital spending grew -3% a year (bottom 48%) (its annual reports). BioLife Solutions, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

BioLife Solutions, Inc.'s newest year against its own record: revenue of $96 million in fiscal 2025 came in 30.3% above the $74 million its prior three years' pace pointed to (top 21% of its family); net income of $5 million against a prior three-year average of $76 million (top 11%); a net margin of -4.8% against losses larger than its revenue before (top 17%) (its annual reports).